| First Author | Otani Y | Year | 2012 |
| Journal | FEBS Lett | Volume | 586 |
| Issue | 20 | Pages | 3639-44 |
| PubMed ID | 22992418 | Mgi Jnum | J:190102 |
| Mgi Id | MGI:5448078 | Doi | 10.1016/j.febslet.2012.08.011 |
| Citation | Otani Y, et al. (2012) Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016. FEBS Lett 586(20):3639-44 |
| abstractText | CXCL12 is a chemokine essential for the organ-specific spread of a variety of cancers including small cell lung cancer (SCLC). Here, we examined the anti-metastatic efficacy of TF14016, a small peptidic inhibitor of CXCL12 receptor CXCR4, in SCLC. Treatment of mice with TF14016 significantly suppressed pulmonary metastases of CXCR4-expressing SCLC in size and number. Furthermore, histological examination revealed that the expression of vascular endothelial cell growth factor and the density of CD31-positive microvessels in metastatic foci were both significantly reduced in TF14016-treated mice. Collectively, CXCR4 could be an attractive target for anti-metastatic and anti-angiogenic therapy in SCLC. |
